Welcome reception

DS working group session
Chairs: Eytan Stein & Courtney DiNardo

Session 1: Understanding the biology and pathogenesis of DS
Chairs: Eytan Stein & Courtney DiNardo

• Corticosteroids and unravelling the spectrum of differentiation syndromes in AML: Justin Watts
• Pathogenesis of DS: Stéphane de Botton
• Initial recognition of differentiation syndrome with ATRA in APL: Ghayas Issa

Panel discussion

Session 2: Clinical presentations and treatment of DS
Chairs: Eytan Stein & Courtney DiNardo

• Patterns of differentiation syndrome in menin-inhibitor treated patient: Ghayas Issa
• Ziftomenib-induced DS: lessons learned: Eunice Wang
  
• Menin inhibitor syndrome: Treatment algorithm and future directions: Joshua Zeidner

Panel discussion

Session summary and close
Chairs: Eytan Stein & Courtney DiNardo

Welcome & introduction
Naval Daver 

Session 1: Translational and lab developments and applications in AML
Chairs: Stephen Nimer & Catherine Smith

• Understanding the biology and therapeutic potential of RAS in frontline AML and CMML: Sandra Misale
• Telomeres and AML: Coleman Lindsley
• Novel targets and targeting approaches for AML immunotherapy: John DiPersio
• Endogenous models of chromosomal alterations driving AML: Sushree Sahoo

Panel discussion

Session 2: New science implications for AML
Chairs: John DiPersio & Coleman Lindsley

• Stem cells in human AML: Asiri Ediriwickrema
• Role of Pi3K gamma inhibition in AML: Andrew Lane
• STAT3 inhibition in MDS and AML: Aditi Shastri

Panel discussion

Break

Keynote talk 1
Proposed updates to the classification of AML: key implications for clinical trials and clinical practice: Robert Hasserjian

Session 3: New frontiers in MRD for AML: Regulatory perspective and clinical practice
Chairs: Naval Daver & Eunice Wang

• Cell-free DNA determinants of AML MRD: Tian Yi Zhang
• MRD as a clinical endpoint in clinical trials: Updates from recent datasets: Gege Gui
• MRD in AML: FDA’s regulatory perspective: Cara Rabik

Panel discussion

Day 1 conclusions
Andrew Wei

Welcome reception

Welcome to Day 2
Gail Roboz

Session 4: Updates on established therapies in AML
Chairs: Andrew Wei & Uma Borate

• Optimal dose of VEN in AML therapy (OPTI-AML): Uma Borate
• Incorporating VEN to IC based induction – current status: Courtney DiNardo
• Optimal dose, duration and de-escalation of venetoclax: Stéphane de Botton

Panel discussion

Keynote talk 2
Targeting fundamental stem cell properties to treat AML: Stephen Nimer

Break

Session 5: Immunotherapies in AML
Chairs: Pinkal Desai & Roland Walter

• AVC-201: A CAR T using a switchable module in AML: Marion Subklewe
• SENTI-202: A logically gated off-the-shelf cell therapy for AML: Stephen Strickland
• Novel targets for T-cell engagers in relapsed/refractory AML: David Sallman
• Pivekimab sunirine: Naval Daver

Panel discussion

Keynote talk 3
Menin inhibitors: mechanisms of sensitivity and resistance: Scott Armstrong

Lunch

Session 6: Targeting FLT3-mutant AML
Chairs: Naval Daver & Catherine Smith

• Frontline approaches for fit patients with FLT3-mutant AML: Naval Daver
• Does the choice of FLT3 inhibitor really matter?: Alexander Perl
• Managing FLT3-ITD+ AML in remission: Eunice Wang
• Resistance mechanisms: Catherine Smith

Panel discussion

Session 7: Value and utility of MRD in the management of adults with newly-diagnosed AML
Chairs: Eunice Wang & Gail Roboz

• Whole genome informed AML diagnosis and MRD testing: Christopher Hourigan
• Debate: NGS-based MRD (when available) is the key surrogate for outcomes for the management of fit adults with newly-diagnosed AML
  • For: Curtis Lachowiez
  • Against: Richard Stone

Panel discussion

 

Break

Session 8: Transplantation in AML
Chairs: Charles Craddock & Victoria Potter

• Strategies to reduce relapse risk post-transplant: Charles Craddock
• Precision-engineered T-cell immunotherapy for alloHSCT: Samer Srour
• Debate: Is pre-transplant intervention warranted in patients with MRD+ AML CR1?
  • Yes: Tapan Kadia
  • No: Uma Borate & Victoria Potter

Panel discussion

Session 9: Clonal hematopoiesis, BPDCN & CMML
Chairs: Naveen Pemmaraju & Uma Borate

• Potential for early intervention in CHIP and CCUS: Updates and ongoing trials: Uma Borate
• Blastic plasmacytoid dendritic cell neoplasm (BPDCN): New approaches: Naveen Pemmaraju
• Molecular biology and clinical outcomes of blast transformed CMML: Mrinal Patnaik

Panel discussion

Day 2 conclusions
Charles Craddock

 

Faculty dinner

Welcome to Day 3
Naval Daver

 

Session 10: Menin inhibitors in AML
Chairs: Naval Daver & Andrew Wei

• Second-generation menin inhibitors, MEN1 mutations, and resistance: Justin Watts
• Menin inhibition for MRD: Ghayas Issa
• Breaking resistance: combinations and next-generation approaches in menin-driven AML: Emma Searle
• Paradigm shift with menin inhibitor triplets: Moving beyond unfit/older AML: Joshua Zeidner

Panel discussion

Keynote talk 4

Novel therapeutic targeting in high-risk genotypes: Ross Levine

Session 11: TP53-mutated AML
Chairs: David Sallman & Eunice Wang

• Biological insights and better understanding TP53m AML: Jayastu Senapati
  
• New approaches to target TP53m AML: Andrew Wei
• TP53-mutated AML and transplant: Pramila Krishnamurthy
• Current challenges and future strategies for TP53-mutated AML and MDS: Maximilian Stahl
• TP53 Potpourri: Gabriel Mannis

Panel discussion

Break

Session 12: Novel targets and advances in our understanding of AML
Chairs: Tapan Kadia & Marina Konopleva

• Beyond genomics: Soluble proteomics in AML: Hussein Abbas
• Molecular complexity in AML: Ann-Kathrin Eisfeld
• Novel targets in AML and their implications for the practicing hematopathologist: Sanam Loghavi
• Reactivating apoptosis in AML: Direct BAX activation as a novel therapeutic strategy: Marina Konopleva
• REM-422: Courtney DiNardo

Panel discussion       

Session 13: Novel combinations and treatments in AML
Chairs: Marina Konopleva & Amir Fathi

• Combinations with AZA/VEN: Thomas Cluzeau
• Intensive or non-intensive induction (PARADIGM): Amir Fathi
• How and when to use oral decitabine in AML: Gail Roboz
• Combination strategies: Hima Atluri
• Diamond-01 trial (MEN1703 [SEL24]): Roland Walter
• Novel combinations in IDH1 mutant AML: Pinkal Desai

Meeting summary and close
Naval Daver